share_log

What 7 Analyst Ratings Have To Say About Health Catalyst

What 7 Analyst Ratings Have To Say About Health Catalyst

7位分析師評級對健康催化劑有何看法
Benzinga ·  04/10 11:00
7 analysts have shared their evaluations of Health Catalyst (NASDAQ:HCAT) during the recent three months, expressing a mix of bullish and bearish perspectives.
近三個月來,7位分析師分享了他們對Health Catalyst(納斯達克股票代碼:HCAT)的評估,他們表達了看漲和看跌的觀點。
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
下表概述了他們最近的評級,簡要介紹了過去30天中不斷變化的情緒,並將其與前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.14, a high estimate of $16.00, and a low estimate of $10.00. This current average reflects an increase of 1.08% from the previous average price target of $13.00.
分析師評估的12個月目標股價揭示了進一步的見解,平均目標價爲13.14美元,最高估計爲16.00美元,低估值爲10.00美元。目前的平均價格比之前的平均目標價13.00美元上漲了1.08%。
Decoding Analyst Ratings: A Detailed Look
解碼分析師評級:詳細介紹
A clear picture of Health Catalyst's perception...
通過對分析師近期...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論